| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
138,140,000 |
| Market
Cap: |
142.28(M) |
| Last
Volume: |
3,241,097 |
Avg
Vol: |
3,286,692 |
| 52
Week Range: |
$0.92 - $1.31 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 807 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Spectrum Pharmaceuticals is a biopharmaceutical company. Co. is engaged in acquiring, developing, and commercializing targeted oncology therapies. Co. has two drugs in late-stage development: Eflapegrastim, which is a long-acting granulocyte colony-stimulating factor for the treatment of chemotherapy-induced neutropenia; as well as Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
50,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$22,500 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
32,387 |
490,738 |
| Total Sell Value |
$0 |
$0 |
$35,496 |
$343,474 |
| Total People Sold |
0 |
0 |
1 |
7 |
| Total Sell Transactions |
0 |
0 |
1 |
19 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gustafson Kurt A |
EVP & Chief Financial Officer |
• – – |
2020-01-16 |
4 |
AS |
$3.37 |
$8,492 |
D/D |
(2,522) |
233,576 |
|
-9% |
|
| Riga Thomas J |
EVP, COO & CCO |
• – – |
2020-01-16 |
4 |
AS |
$3.37 |
$38,320 |
D/D |
(11,381) |
246,678 |
|
-9% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2019-11-06 |
4 |
AS |
$8.16 |
$56,825 |
D/D |
(6,963) |
113,970 |
|
- |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2019-08-12 |
4 |
AS |
$7.77 |
$2,283 |
D/D |
(294) |
135,543 |
|
- |
|
| Czerepak Elizabeth |
Director |
– • – |
2019-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
| Cohen Raymond W |
Director |
– • – |
2019-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
53,850 |
|
- |
|
| Ashton William |
Director |
– • – |
2019-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
16,666 |
|
- |
|
| Ashton William |
Director |
– • – |
2019-06-20 |
4 |
AS |
$8.50 |
$14,170 |
D/D |
(1,667) |
6,666 |
|
- |
|
| Vacirca Jeff L |
Director |
– • – |
2019-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
31,967 |
|
- |
|
| Welles Bernice R |
Director |
– • – |
2019-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,000 |
|
- |
|
| Vyas Dolatrai |
Director |
– • – |
2019-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
51,069 |
|
- |
|
| Lebel Francois |
Chief Medical OfficerOfficer |
• – – |
2019-06-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
948 |
|
- |
|
| Lebel Francois |
Chief Medical OfficerOfficer |
• – – |
2019-06-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
70,250 |
|
- |
|
| Ashton William |
Director |
– • – |
2019-06-19 |
4 |
AS |
$8.59 |
$42,950 |
D/D |
(5,000) |
8,333 |
|
- |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2019-06-19 |
4 |
AS |
$8.49 |
$30,002 |
D/D |
(3,535) |
135,756 |
|
- |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2019-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
120,250 |
|
- |
|
| Turgeon Joseph W. |
CEO & President |
• • – |
2019-06-06 |
4 |
AS |
$7.95 |
$145,070 |
D/D |
(18,240) |
430,977 |
|
- |
|
| Maida Anthony E III |
Director |
– • – |
2019-05-29 |
4 |
S |
$7.75 |
$330,355 |
D/D |
(42,643) |
29,607 |
|
- |
|
| Maida Anthony E III |
Director |
– • – |
2019-05-29 |
4 |
OE |
$6.09 |
$304,500 |
D/D |
50,000 |
72,250 |
|
- |
|
| Krassner Stuart Mitchell |
Director |
– • – |
2019-05-28 |
4 |
S |
$8.00 |
$299,080 |
D/D |
(37,385) |
75,488 |
|
- |
|
| Krassner Stuart Mitchell |
Director |
– • – |
2019-05-28 |
4 |
OE |
$6.09 |
$273,618 |
D/D |
44,929 |
112,873 |
|
- |
|
| Krassner Stuart Mitchell |
Director |
– • – |
2019-05-24 |
4 |
S |
$7.94 |
$40,264 |
D/D |
(5,071) |
67,944 |
|
- |
|
| Krassner Stuart Mitchell |
Director |
– • – |
2019-05-24 |
4 |
OE |
$6.09 |
$30,882 |
D/D |
5,071 |
73,015 |
|
- |
|
| Turgeon Joseph W. |
CEO & President |
• • – |
2019-05-16 |
4 |
AS |
$8.53 |
$193,755 |
D/D |
(22,702) |
449,217 |
|
- |
|
| Riga Thomas J |
EVP, COO & CCO |
• – – |
2019-05-14 |
4 |
AS |
$8.82 |
$21,069 |
D/D |
(2,388) |
258,035 |
|
- |
|
658 Records found
|
|
Page 8 of 27 |
|
|
